Here's Why Bellicum Pharmaceuticals Lost 13.8% in July
The clinical-stage biopharma just can't catch a break from Wall Street.
Saturday, August 4, 2018
Here's Why Bellicum Pharmaceuticals Lost 13.8% in July
Here's Why Bellicum Pharmaceuticals Lost 13.8% in July
The clinical-stage biopharma just can't catch a break from Wall Street.
Related Posts:
Gap cuts profit forecast after 'extremely challenging' quarter; shares slump 11%- Dell planning for potential fourth round of U.S. tariffs
- Major Hollywood studios may reconsider Georgia business over abortion law
- Uber loses $1 billion in quarter as costs grow for drivers, food delivery
- Dell revenue misses as China softness hits server business
0 comments:
Post a Comment